AZN said it entered into an exclusive global license agreement with China's Dizal Pharmaceutical for the lung cancer treatment drug Zegfrovy
AZN said it entered into an exclusive global license agreement with China's Dizal Pharmaceutical for the lung cancer treatment drug Zegfrovy, in a deal valued at up to $1.5B; said it would make an upfront payment of $600B, as well as additional payments of up to $900M of milestones
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.